TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Trial Profile

TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs PSMA 617 (Primary) ; Cabazitaxel
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TheraP
  • Most Recent Events

    • 26 Jun 2018 According to an Endocyte media release, an image of PET scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment from this trial was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the Image of the Year.
    • 16 May 2018 According to Endocyte media release, data from this trial will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 30 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top